Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials
- PMID: 23504141
- PMCID: PMC3705144
- DOI: 10.1245/s10434-013-2887-8
Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials
Abstract
Background: Sentinel lymph node (SLN) surgery is used worldwide for staging breast cancer patients and helps limit axillary lymph node dissection. [(99m)Tc]Tilmanocept is a novel receptor-targeted radiopharmaceutical evaluated in 2 open-label, nonrandomized, within-patient, phase 3 trials designed to assess the lymphatic mapping performance.
Methods: A total of 13 centers contributed 148 patients with breast cancer. Each patient received [(99m)Tc]tilmanocept and vital blue dye (VBD). Lymph nodes identified intraoperatively as radioactive and/or blue stained were excised and histologically examined. The primary endpoint, concordance (lower boundary set point at 90 %), was the proportion of nodes detected by VBD and [(99m)Tc]tilmanocept.
Results: A total of 13 centers contributed 148 patients who were injected with both agents. Intraoperatively, 207 of 209 nodes detected by VBD were also detected by [(99m)Tc]tilmanocept for a concordance rate of 99.04 % (p < 0.0001). [(99m)Tc]tilmanocept detected a total of 320 nodes, of which 207 (64.7 %) were detected by VBD. [(99m)Tc]Tilmanocept detected at least 1 SLN in more patients (146) than did VBD (131, p < 0.0001). In 129 of 131 patients with ≥1 blue node, all blue nodes were radioactive. Of 33 pathology-positive nodes (18.2 % patient pathology rate), [(99m)Tc]tilmanocept detected 31 of 33, whereas VBD detected only 25 of 33 (p = 0.0312). No pathology-positive SLNs were detected exclusively by VBD. No serious adverse events were attributed to [(99m)Tc]tilmanocept.
Conclusion: [(99m)Tc]Tilmanocept demonstrated success in detecting a SLN while meeting the primary endpoint. Interestingly, [(99m)Tc]tilmanocept was additionally noted to identify more SLNs in more patients. This localization represented a higher number of metastatic breast cancer lymph nodes than that of VBD.
Figures


Similar articles
-
Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma.Ann Surg Oncol. 2013 Feb;20(2):680-8. doi: 10.1245/s10434-012-2612-z. Epub 2012 Oct 3. Ann Surg Oncol. 2013. PMID: 23054107 Free PMC article. Clinical Trial.
-
Comparison of [(99m)Tc]tilmanocept and filtered [(99m)Tc]sulfur colloid for identification of SLNs in breast cancer patients.Ann Surg Oncol. 2015 Jan;22(1):40-5. doi: 10.1245/s10434-014-3892-2. Epub 2014 Jul 29. Ann Surg Oncol. 2015. PMID: 25069859 Free PMC article.
-
A phase 2 study of (99m)Tc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer.Ann Surg Oncol. 2011 Apr;18(4):961-9. doi: 10.1245/s10434-010-1524-z. Epub 2011 Feb 18. Ann Surg Oncol. 2011. PMID: 21331809 Free PMC article. Clinical Trial.
-
The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: a comparative review and meta-analysis of the ⁹⁹mTc-labeled nanocolloid human serum albumin standard of care.Clin Exp Metastasis. 2012 Oct;29(7):681-6. doi: 10.1007/s10585-012-9497-x. Epub 2012 Jun 23. Clin Exp Metastasis. 2012. PMID: 22729510 Review.
-
Detection of melanoma, breast cancer and head and neck squamous cell cancer sentinel lymph nodes by Tc-99m Tilmanocept (Lymphoseek®).Clin Exp Metastasis. 2022 Feb;39(1):39-50. doi: 10.1007/s10585-021-10137-4. Epub 2021 Dec 28. Clin Exp Metastasis. 2022. PMID: 34962630 Free PMC article. Review.
Cited by
-
Repurposing Molecular Imaging and Sensing for Cancer Image-Guided Surgery.J Nucl Med. 2020 Aug;61(8):1113-1122. doi: 10.2967/jnumed.118.220426. Epub 2020 Apr 17. J Nucl Med. 2020. PMID: 32303598 Free PMC article. Review.
-
Carbohydrate-based drugs launched during 2000-2021.Acta Pharm Sin B. 2022 Oct;12(10):3783-3821. doi: 10.1016/j.apsb.2022.05.020. Epub 2022 May 23. Acta Pharm Sin B. 2022. PMID: 36213536 Free PMC article. Review.
-
A pilot study of lymphoscintigraphy with tracer injection into the human brain.J Cereb Blood Flow Metab. 2023 Aug;43(8):1382-1389. doi: 10.1177/0271678X231160891. Epub 2023 Mar 30. J Cereb Blood Flow Metab. 2023. PMID: 36994857 Free PMC article.
-
Optimization via specific fluorescence brightness of a receptor-targeted probe for optical imaging and positron emission tomography of sentinel lymph nodes.J Biomed Opt. 2013 Oct;18(10):101315. doi: 10.1117/1.JBO.18.10.101315. J Biomed Opt. 2013. PMID: 23958947 Free PMC article.
-
Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 111In-tilmanocept.EJNMMI Res. 2017 Dec;7(1):40. doi: 10.1186/s13550-017-0287-y. Epub 2017 May 3. EJNMMI Res. 2017. PMID: 28470406 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical